| Peptidase Inhibition and Analysis | Lifetime | 7 | FR 1 | 99.96 |
| Multiple Myeloma Research and Treatments | Lifetime | 6 | FR 1 | 99.97 |
| Protein Degradation and Inhibitors | Lifetime | 6 | FR 1 | 99.94 |
| Cancer Treatment and Pharmacology | Lifetime | 22 | FR 1 | 99.90 |
| Cancer Mechanisms and Therapy | Lifetime | 38 | FR 2 | 99.29 |
| Ubiquitin and proteasome pathways | Lifetime | 91 | FR 2 | 99.45 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 121 | FR 8 | 99.60 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 344 | FR 7 | 99.33 |
| CAR-T cell therapy research | Lifetime | 255 | FR 17 | 99.16 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 97 | FR 4 | 99.13 |
| Lymphoma Diagnosis and Treatment | Lifetime | 303 | FR 15 | 99.12 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 76 | FR 3 | 98.80 |
| Cancer therapeutics and mechanisms | Lifetime | 210 | FR 8 | 98.76 |
| Hematopoietic Stem Cell Transplantation | Lifetime | 262 | FR 14 | 98.86 |
| Histone Deacetylase Inhibitors Research | Lifetime | 209 | FR 7 | 97.88 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 356 | FR 10 | 97.15 |
| HIV/AIDS drug development and treatment | Lifetime | 991 | FR 63 | 97.04 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 905 | FR 51 | 96.34 |
| Neutropenia and Cancer Infections | Lifetime | 616 | FR 42 | 95.11 |
| Hematological disorders and diagnostics | Lifetime | 624 | FR 25 | 92.74 |
| Phytochemical compounds biological activities | Lifetime | 516 | FR 13 | 92.52 |
| CNS Lymphoma Diagnosis and Treatment | Lifetime | 846 | FR 84 | 91.14 |
| Beetle Biology and Toxicology Studies | Lifetime | 302 | FR 5 | 68.99 |
| Lymphadenopathy Diagnosis and Analysis | Lifetime | 536 | FR 36 | 31.75 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 3 | FR 1 | 99.96 |
| Peptidase Inhibition and Analysis | 2021-2025 | 3 | FR 1 | 99.86 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 6 | FR 1 | 99.80 |
| Protein Degradation and Inhibitors | 2021-2025 | 3 | FR 1 | 99.92 |
| CAR-T cell therapy research | 2021-2025 | 42 | FR 4 | 99.64 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 52 | FR 2 | 99.27 |
| Cancer Treatment and Pharmacology | 2021-2025 | 66 | FR 3 | 98.64 |
| Cancer Mechanisms and Therapy | 2021-2025 | 42 | FR 2 | 96.72 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 159 | FR 8 | 96.15 |
| HIV/AIDS drug development and treatment | 2021-2025 | 170 | FR 9 | 94.51 |
| Cancer therapeutics and mechanisms | 2021-2025 | 163 | FR 6 | 90.62 |
| Ubiquitin and proteasome pathways | 2021-2025 | 625 | FR 5 | 85.61 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 284 | FR 7 | 78.50 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 579 | FR 24 | 80.11 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 943 | FR 50 | 75.63 |
| Quinazolinone synthesis and applications | 2021-2025 | 759 | FR 10 | 57.75 |
| Chemokine receptors and signaling | 2021-2025 | 683 | FR 24 | 55.59 |
| Natural Product Synthesis and Anticancer Bioactivity | 2021-2025 | 153 | FR 1 | 47.56 |
